Thierry Bouyssou, Ingelheim am Rhein (DE); Dirk Gottschling, Ingelheim am Rhein (DE); Niklas Heine, Ingelheim am Rhein (DE); Lana Louise Smith Keenan, Poughquag, NY (US); Michael D. Lowe, Pleasantville, NY (US); Hossein Razavi, Danbury, CT (US); Christopher Ronald Sarko, San Ramon, CA (US); Simon Surprenant, Boisbriand (CA); Hidenori Takahashi, LaGrangeville, NY (US); Michael Robert Turner, Danbury, CT (US); and Xinyuan Wu, Newton, MA (US)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE); and Hydra Biosciences, LLC, Belmont, MA (US)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE); and Hydra Biosciences, LLC, Belmont, MA (US)
Filed on May 28, 2021, as Appl. No. 17/334,097.
Application 17/334,097 is a reissue of application No. 16/170,154, filed on Oct. 25, 2018, granted, now 10,800,757, issued on Oct. 13, 2020.
Claims priority of provisional application 62/628,313, filed on Feb. 9, 2018.
Claims priority of provisional application 62/577,883, filed on Oct. 27, 2017.
[ 29. The compound of claim 19, which is [4-(6-Amino-pyridazin-3-yl)-piperidin-1-yl]-[5-(4-isopropoxy-phenoxy)-4-methoxy-pyridin-2-yl]-methanone, or a pharmaceutically acceptable salt thereof. ]